Aspire Biopharma Holdings, Inc.
ASBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001847345
No open-market purchases or sales by Aspire Biopharma Holdings, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $250.9K in total; no superinvestor holds it.
Other share classesASBPW
13F holders, Q3 2025
Institutional positions in Aspire Biopharma Holdings, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- +9 vs. Q2 2025
- Shares held
- 3.12M
- +1.08M (+52.8%) vs. Q2 2025
- Total value
- $645.6K
- +$100.9K (+18.5%) vs. Q2 2025
- New holders
- 12
- 3 more added
- Sold out
- 3
- 4 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ASBP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 13 | $250.9K |
| Q1 2026 | 15 | $371.9K |
| Q4 2025 | 30 | $899.8K |
| Q3 2025 | 25 | $645.6K |
| Q2 2025 | 16 | $544.7K |
| Q1 2025 | 15 | $875.8K |
| Q4 2024 | 3 | $5.36M |
| Q3 2024 | 2 | $149.6K |
| Q2 2024 | 3 | $90.4K |
| Q1 2024 | 19 | $18.1M |
| Q4 2023 | 21 | $17.9M |
| Q3 2023 | 21 | $18.2M |
| Q2 2023 | 14 | $17.0M |
| Q1 2023 | 59 | $267.9M |
| Q4 2022 | 57 | $264.7M |
| Q3 2022 | 61 | $260.8M |
| Q2 2022 | 54 | $243.4M |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Aspire Biopharma Holdings, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Crewe Advisors LLC | 813,427 | $167.6K | 0.02% | +186,573+29.8% | Added |
| Procyon Private Wealth Partners, LLC | 472,661 | $97.4K | 0.01% | −175,750−27.1% | Reduced |
| Vanguard Group Inc | 428,552 | $88.3K | 0.00% | +428,552 | New |
| Optivise Advisory Services LLC | 263,522 | $54.3K | 0.03% | +28,416+12.1% | Added |
| Geode Capital Management, LLC | 250,161 | $51.5K | 0.00% | +250,161 | New |
| Antara Capital LP | 202,897 | $41.8K | 8.53% | +202,897 | New |
| VR Advisory Services Ltd | 97,391 | $20.1K | 0.00% | 00.0% | Unchanged |
| Resolute Partners Group | 82,783 | $17.1K | 0.00% | +82,783 | New |
| Three Seasons Wealth, LLC | 75,000 | $15.4K | 0.00% | 00.0% | Unchanged |
| P Schoenfeld Asset Management LP | 58,563 | $12.1K | 0.00% | +58,563 | New |
| Avion Wealth | 54,113 | $11.0K | 0.00% | +54,113 | New |
| Periscope Capital Inc. | 50,000 | $10.3K | 0.00% | −25,000−33.3% | Reduced |
| CIBC Private Wealth Group, LLC | 49,129 | $10.1K | 0.00% | +42,021+591.2% | Added |
| Hallmark Capital Management Inc | 40,000 | $8.24K | 0.00% | 00.0% | Unchanged |
| Platform Technology Partners | 37,611 | $7.75K | 0.00% | 00.0% | Unchanged |
| Crossingbridge Advisors, LLC | 24,348 | $7.42K | 0.00% | +24,348 | New |
| Tower Research Capital LLC (TRC) | 31,120 | $6.41K | 0.00% | +31,120 | New |
| Jane Street Group, LLC | 29,257 | $6.03K | 0.00% | −123,295−80.8% | Reduced |
| XTX Topco Ltd | 27,851 | $5.74K | 0.00% | +27,851 | New |
| Colony Group, LLC | 12,538 | $2.58K | 0.00% | +12,538 | New |
| Allred Capital Management, LLC | 11,185 | $2.30K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 7,661 | $1.58K | 0.00% | +7,661 | New |
| SOA Wealth Advisors, LLC. | 2,920 | $602 | 0.00% | +2,920 | New |
| Bank of America Corp | 253 | $52 | 0.00% | −18−6.6% | Reduced |
| Advisor Group Holdings, Inc. | 100 | $20 | 0.00% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −18,701−100.0% | Sold out |
| Scientech Research LLC | 0 | $0 | 0.00% | −16,514−100.0% | Sold out |
| Raymond James Financial Inc | 0 | $0 | 0.00% | −2,500−100.0% | Sold out |